BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11343385)

  • 21. Platelet functional defects in women with unexplained menorrhagia.
    Philipp CS; Dilley A; Miller CH; Evatt B; Baranwal A; Schwartz R; Bachmann G; Saidi P
    J Thromb Haemost; 2003 Mar; 1(3):477-84. PubMed ID: 12871453
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dominant von Willebrand disease type 2M and 2U are variable expressions of one distinct disease entity caused by loss-of-function mutations in the A1 domain of the von Willebrand factor gene.
    Gadisseur A; van der Planken M; Schroyens W; Berneman Z; Michiels JJ
    Acta Haematol; 2009; 121(2-3):145-53. PubMed ID: 19506361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. What have we learned from large population studies of von Willebrand disease?
    Montgomery RR; Flood VH
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):670-677. PubMed ID: 27913545
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recessive von Willebrand disease type 2 Normandy: variable expression of mild hemophilia and VWD type 1.
    Michiels JJ; Gadisseur A; Vangenegten I; Schroyens W; Berneman Z
    Acta Haematol; 2009; 121(2-3):119-27. PubMed ID: 19506358
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive re-evaluation of historical von Willebrand disease diagnosis in association with whole blood platelet aggregation and function.
    Nummi V; Lassila R; Joutsi-Korhonen L; Armstrong E; Szanto T
    Int J Lab Hematol; 2018 Jun; 40(3):304-311. PubMed ID: 29427305
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 2M von Willebrand disease variant characterized by abnormal von willebrand factor multimerization.
    Casonato A; Pontara E; Sartorello F; Bertomoro A; Durante C; Girolami A
    J Lab Clin Med; 2001 Jan; 137(1):70-6. PubMed ID: 11150026
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of recessive severe type 1 and 3 von Willebrand Disease (VWD), asymptomatic heterozygous carriers versus bloodgroup O-related von Willebrand factor deficiency, and dominant type 1 VWD.
    Michiels JJ; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van de Velde A; van Vliet H
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):277-95. PubMed ID: 16959681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous DDAVP and factor VIII-von Willebrand factor concentrate for the treatment and prophylaxis of bleedings in patients With von Willebrand disease type 1, 2 and 3.
    Michiels JJ; van Vliet HH; Berneman Z; Gadisseur A; van der Planken M; Schroyens W; van der Velden A; Budde U
    Clin Appl Thromb Hemost; 2007 Jan; 13(1):14-34. PubMed ID: 17164493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Standardisation of factor VIII and von Willebrand factor in plasma: calibration of the 4th International Standard (97/586).
    Hubbard AR; Rigsby P; Barrowcliffe TW
    Thromb Haemost; 2001 Apr; 85(4):634-8. PubMed ID: 11341497
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet-type von Willebrand disease platelet aggregating factor: a novel functional assay of von Willebrand factor.
    Takahashi H; Tatewaki W; Hanano M; Shibata A
    Thromb Res; 1987 Nov; 48(4):475-85. PubMed ID: 3127926
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Impact of plasma von Willebrand factor levels in the diagnosis of type 1 von Willebrand disease: results from a multicenter European study (MCMDM-1VWD).
    Tosetto A; Rodeghiero F; Castaman G; Bernardi M; Bertoncello K; Goodeve A; Federici AB; Batlle J; Meyer D; Mazurier C; Goudemand J; Eikenboom J; Schneppenheim R; Budde U; Ingerslev J; Vorlova Z; Habart D; Holmberg L; Lethagen S; Pasi J; Hill F; Peake I
    J Thromb Haemost; 2007 Apr; 5(4):715-21. PubMed ID: 17408405
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bleeding prophylaxis for major surgery in patients with type 2 von Willebrand disease with an intermediate purity factor VIII-von Willebrand factor concentrate (Haemate-P).
    Michiels JJ; Berneman ZN; van der Planken M; Schroyens W; Budde U; van Vliet HH
    Blood Coagul Fibrinolysis; 2004 Jun; 15(4):323-30. PubMed ID: 15166918
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Laboratory diagnosis of von Willebrand disease type 1/2E (2A subtype IIE), type 1 Vicenza and mild type 1 caused by mutations in the D3, D4, B1-B3 and C1-C2 domains of the von Willebrand factor gene. Role of von Willebrand factor multimers and the von Willebrand factor propeptide/antigen ratio.
    Gadisseur A; Berneman Z; Schroyens W; Michiels JJ
    Acta Haematol; 2009; 121(2-3):128-38. PubMed ID: 19506359
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current and emerging approaches for assessing von Willebrand disease in 2016.
    Federici AB
    Int J Lab Hematol; 2016 May; 38 Suppl 1():41-9. PubMed ID: 27426859
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Diagnosis and classification of von Willebrand disease: a review of the differential utility of various functional von Willebrand factor assays.
    Favaloro EJ
    Blood Coagul Fibrinolysis; 2011 Oct; 22(7):553-64. PubMed ID: 21885953
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heat-treated factor VIII/von Willebrand factor concentrate in platelet-type von Willebrand's disease.
    Takahashi H; Tatewaki W; Nagayama R; Hanano M; Tamura M; Yamaguchi T; Takizawa S; Wada K; Shibata A
    Haemostasis; 1987; 17(6):353-60. PubMed ID: 3123334
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Laboratory assays for von Willebrand factor: relative contribution to the diagnosis of von Willebrand's disease.
    Favaloro EJ; Koutts J
    Pathology; 1997 Nov; 29(4):385-91. PubMed ID: 9423220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Validation of a new panel of automated chemiluminescence assays for von Willebrand factor antigen and activity in the screening for von Willebrand disease.
    Verfaillie CJ; De Witte E; Devreese KM
    Int J Lab Hematol; 2013 Oct; 35(5):555-65. PubMed ID: 23551532
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An evaluation of the DDAVP infusion test with PFA-100 and vWF activity assays to distinguish vWD types in children.
    Akin M; Karapinar DY; Balkan C; Ay Y; Kavakli K
    Clin Appl Thromb Hemost; 2011 Oct; 17(5):441-8. PubMed ID: 20460340
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.